Literature DB >> 30747702

Position paper on laboratory testing for patients with haemophilia. A consensus document from SISET, AICE, SIBioC and SIPMeL.

Armando Tripodi1, Rita C Santoro2, Sophie Testa3, Angelo C Molinari4, Sergio Bernardini5, Maria Golato6, Giuseppe Lippi7, Walter Ageno8, Elena Santagostino1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30747702      PMCID： PMC6596380          DOI： 10.2450/2019.0241-18

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  35 in total

1.  Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.

Authors:  G C White; F Rosendaal; L M Aledort; J M Lusher; C Rothschild; J Ingerslev
Journal:  Thromb Haemost       Date:  2001-03       Impact factor: 5.249

2.  Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.

Authors:  S Tiefenbacher; R Bohra; J Amiral; A Bowyer; S Kitchen; A Lochu; S Rosén; M Ezban
Journal:  J Thromb Haemost       Date:  2017-09-11       Impact factor: 5.824

Review 3.  Defining severity of hemophilia: more than factor levels.

Authors:  Anna Pavlova; Johannes Oldenburg
Journal:  Semin Thromb Hemost       Date:  2013-09-11       Impact factor: 4.180

4.  Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.

Authors:  P Rosén; S Rosén; M Ezban; E Persson
Journal:  J Thromb Haemost       Date:  2016-06-22       Impact factor: 5.824

5.  International comparative field study of N8 evaluating factor VIII assay performance.

Authors:  D Viuff; Tw Barrowcliffe; T Saugstrup; M Ezban; D Lillicrap
Journal:  Haemophilia       Date:  2011-03-22       Impact factor: 4.287

6.  Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.

Authors:  A Hillarp; A Bowyer; M Ezban; P Persson; S Kitchen
Journal:  Haemophilia       Date:  2017-02-14       Impact factor: 4.287

7.  International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories.

Authors:  K St Ledger; A Feussner; U Kalina; C Horn; H J Metzner; D Bensen-Kennedy; N Blackman; A Veldman; A Stowers; K D Friedman
Journal:  J Thromb Haemost       Date:  2018-02-01       Impact factor: 5.824

Review 8.  The past and future of haemophilia: diagnosis, treatments, and its complications.

Authors:  Flora Peyvandi; Isabella Garagiola; Guy Young
Journal:  Lancet       Date:  2016-02-18       Impact factor: 79.321

9.  Measurement of B-domain-deleted ReFacto AF activity with a product-specific standard is affected by choice of reagent and patient-specific factors.

Authors:  M Jacquemin; A Vodolazkaia; J Toelen; J Schoeters; I Van Horenbeeck; I Vanlinthout; M Debasse; K Peerlinck
Journal:  Haemophilia       Date:  2017-01-25       Impact factor: 4.287

10.  Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.

Authors:  P Chowdary; S Lethagen; U Friedrich; B Brand; C Hay; F Abdul Karim; R Klamroth; P Knoebl; M Laffan; J Mahlangu; W Miesbach; J Dalsgaard Nielsen; M Martín-Salces; P Angchaisuksiri
Journal:  J Thromb Haemost       Date:  2015-04-06       Impact factor: 5.824
View more
  6 in total

1.  Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels.

Authors:  Nasim Shahidi Hamedani; Johannes Oldenburg; Bernd Pötzsch; Jens Müller
Journal:  PLoS One       Date:  2022-07-14       Impact factor: 3.752

Review 2.  Current therapeutic approaches in the management of hemophilia-a consensus view by the Romanian Society of Hematology.

Authors:  Ionut Hotea; Melen Brinza; Cristina Blag; Alina-Andreea Zimta; Noemi Dirzu; Corina Burzo; Ioana Rus; Dragos Apostu; Horea Benea; Mirela Marian; Alexandru Mester; Sergiu Pasca; Sabina Iluta; Patric Teodorescu; Ciprian Jitaru; Mihnea Zdrenghea; Anca Bojan; Tunde Torok-Vistai; Radu Niculescu; Cristina Tarniceriu; Delia Dima; Cristina Truica; Margit Serban; Ciprian Tomuleasa; Daniel Coriu
Journal:  Ann Transl Med       Date:  2021-07

3.  Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A.

Authors:  Angelika Batorova; Ana Boban; Melen Brinza; Toshiko Lissitchkov; Laszlo Nemes; Irena Zupan Preložnik; Petr Smejkal; Nadezhda Zozulya; Jerzy Windyga
Journal:  J Med Life       Date:  2022-04

4.  Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study.

Authors:  Anouk A M T Donners; László Gerencsér; Kim C M van der Elst; Toine C G Egberts; Moniek P M de Maat; Albert Huisman; Rolf T Urbanus; Mohsin El Amrani
Journal:  Res Pract Thromb Haemost       Date:  2022-06-08

5.  Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.

Authors:  Giancarlo Castaman; Cristina Santoro; Antonio Coppola; Maria E Mancuso; Rita C Santoro; Sergio Bernardini; Francesco R Pugliese; Riccardo Lubrano; Maria Golato; Armando Tripodi; Angiola Rocino; Elena Santagostino; Chiara Biasoli; Alessandra Borchiellini; Alberto Catalano; Laura Contino; Antonella Coluccia; Dorina Cultrera; Raimondo De Cristofaro; Giovanni Di Minno; Andrea Fabbri; Massimo Franchini; Gabriella Gamba; Anna Chiara Giuffrida; Paolo Gresele; Adele Giampaolo; Hamisa J Hassan; Matteo Luciani; Emanuela Marchesini; Renato Marino; Maria Gabriella Mazzucconi; Angelo C Molinari; Massimo Morfini; Lucia D Notarangelo; Lucia Peccarisi; Flora Peyvandi; Berardino Pollio; Gianna Franca Rivolta; Maria Pia Ruggieri; Vittorio Sargentini; Mario Schiavoni; Laura Sciacovelli; Maria Luisa Serino; Sergio Siragusa; Annarita Tagliaferri; Sophie Testa; Alberto Tosetto; Stefania Zampogna; Ezio Zanon
Journal:  Blood Transfus       Date:  2019-10-18       Impact factor: 3.443

6.  Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus.

Authors:  Antonio Coppola; Massimo Franchini; Giovanni Pappagallo; Alessandra Borchiellini; Raimondo De Cristofaro; Angelo Claudio Molinari; Rita Carlotta Santoro; Cristina Santoro; Annarita Tagliaferri
Journal:  J Clin Med       Date:  2022-02-02       Impact factor: 4.241
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.